Context

Patients with type 2 diabetes (T2D) are exposed to a high risk of cardiovascular disease (CVD) and premature mortality. A multirisk approach has proven to reduce both major cardiovascular events and mortality.1 However, improved longevity may lead to a higher risk of developing other diabetic complications, among which chronic kidney disease represents a major burden.

Inhibitors of renal sodium-glucose cotransporters type 2 (SGLT2) are oral glucose-lowering agents that promote glucosuria and dampen glucotoxicity, but also reduce body weight, arterial blood pressure and hyperuricaemia.2 By reducing these risk factors, SGLT2 inhibitors offer promise to reduce cardiovascular and renal outcomes in patients with T2D.